Drug Trial Radar · NCT06044350
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
162
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .
Conditions
- Optic Neuromyelitis Spectrum Disease
Interventions
BAT4406F InjectionDrug
Intravenous infusion; Dosage:500mg/time
BAT4406F PlacebosDrug
Intravenous infusion; Dosage:500mg/time
Primary outcomes
What the sponsor says the trial is designed to measure.
- PharmacodynamicsTime frame: RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years
- PharmacodynamicsTime frame: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
- PharmacodynamicsTime frame: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Pharmacokinetics(PK)Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.
- Immunogenicity evaluationTime frame: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
- Immunogenicity evaluationTime frame: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
Baotou, China
Beijing Hospital
Beijing, China
China-japan friendship Hospital
Beijing, China
The first hospital of Peking University
Beijing, China
The Central South University Xiang Ya Hospital
Changsha, China
Xiangya 2nd hospital of central south university
Changsha, China
First affiliated hospital of chongqing medical university
Chongqing, China
The first affiliated hospital of Dalian Medical University
Dalian, China
First affiliated hospital of fujian medical university
Fuzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
The first hospital affiliated to sun yat-sen university
Guangzhou, China
The first People's Hospital of Guangzhou
Guangzhou, China
The third hospital affiliated to sun yat-sen university
Guangzhou, China
People's Hospital of Zhejiang province
Hangzhou, China
Anhui Provincial Hospital
Hefei, China
Second Affiliated Hospital of Anhui Medical University
Hefei, China
Shandong University Qilu Hospital
Jinan, China
Jingzhou Central Hospital
Jingzhou, China
First Affiliated Hospital of the Kunming Medical University
Kunming, China
Second Affiliated Hospital of Nanchang University
Nanchang, China
Affiliated Hospital of North Sichuan Medical College
Nanchong, China
Drum Tower Hospital affiliated to Medical College of Nanjing University
Nanjing, China
Southeast university affiliated zhongda hospital
Nanjing, China
The Chinese people's liberation army general hospital in eastern theater
Nanjing, China
The first People's Hospital of Nantong
Nantong, China
Qingdao municipal hospital
Qingdao, China
Mount Hua Hospital affiliated to Fudan University
Shanghai, China
Shuguang hospital affiliated to Shanghai University of Traditional Chinese medicine
Shanghai, China
Zhongshan hospital affiliated to Fudan University
Shanghai, China
Shenzhen city people's hospital
Shenzhen, China
Second Hebei Medical University Hospital
Shijia Zhuang, China
The Third Hospital of Hebei Medical University
Shijiazhuang, China
First Affiliated Hospital of Suzhou University
Suzhou, China
The Second Affiliated Hospital of Suzhou University
Suzhou, China
The first hospital of shanxi medical university
Taiyuan, China
Tianjin Medical University General Hospital
Tianjin, China
The first hospital affiliated to wenzhou medical college
Wenzhou, China
Tongji hospital affiliated to tongji medical college huazhong university of science and technology
Wuhan, China
Xiehe hospital affiliated to tongji medical college huazhong university of science and technology
Wuhan, China
Wuxi city people's hospital
Wuxi, China
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.